Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Testosterone replacement therapy and cardiovascular disease

Abstract

The use of testosterone therapy has a complex history of apprehension and questions regarding its safety. Despite an eventual consensus that testosterone therapy was safe and effective, several studies relating to cardiovascular risks emerged in the last decade, rekindling skepticism regarding the safety of testosterone therapy. Given the utility of testosterone therapy in treating the symptoms of hypogonadism, it remains crucial to closely examine the safety of testosterone therapy. The present article synthesizes the current evidence regarding cardiovascular risks that may be associated with testosterone therapy, the potential mechanisms regarding testosterone’s efficacy, and future directions in evaluating the safety of its use.

This is a preview of subscription content, access via your institution

Access options

Buy article

Get time limited or full article access on ReadCube.

$32.00

All prices are NET prices.

References

  1. Tsametis CP, Isidori AM. Testosterone replacement therapy: for whom, when and how?. Metabolism. 2018;86:69–78. https://doi.org/10.1016/j.metabol.2018.03.007.

    Article  CAS  PubMed  Google Scholar 

  2. Smith JB, Rosen J, Colbert A. Low serum testosterone in outpatient psychiatry clinics: addressing challenges to the screening and treatment of hypogonadism. Sex Med Rev. 2018;6:69–76. https://doi.org/10.1016/j.sxmr.2017.08.007.

    Article  PubMed  Google Scholar 

  3. Dohle G, Arver S, Bettocchi C, Jones T, Kliesch S, Punab M. Guidelines on male hypogonadism. Eur Assoc Urol. 2015. https://doi.org/10.1007/978-1-60761-193-6.

    Article  Google Scholar 

  4. Huggins C, Hodges CV. Studies on prostatic cancer i. the effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res. 1941;22:232–40. https://doi.org/10.3322/canjclin.22.4.232.

    Article  Google Scholar 

  5. Roddam AW, Allen NE, Appleby P, Key TJ. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. J Natl Cancer Inst. 2008;100:170–83. https://doi.org/10.1093/jnci/djm323.

    Article  CAS  PubMed  Google Scholar 

  6. Rhoden EL, Morgentaler A. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med. 2004;350:482–92. https://doi.org/10.1056/NEJMra022251.

    Article  CAS  PubMed  Google Scholar 

  7. Morgentaler A, Traish A. The history of testosterone and the evolution of its therapeutic potential. Sex Med Rev. 2020;8:286–96. https://doi.org/10.1016/j.sxmr.2018.03.002.

    Article  PubMed  Google Scholar 

  8. Morgentaler A, Miner MM, Caliber M, Guay AT, Khera M, Traish AM. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90:224–51. https://doi.org/10.1016/j.mayocp.2014.10.011.

    Article  CAS  PubMed  Google Scholar 

  9. Basaria S, Coviello AD, Travison TG, Storer TW, Farwell WR, Jette AM, et al. Adverse events associated with testosterone administration. N. Engl J Med. 2010;363:109–22. https://doi.org/10.1056/NEJMoa1000485.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. US Food and Drug Administration. Citizen petition denial response from FDA CDER to public citizen. 2014. http://www.citizen.org/documents/2184_FDA%20Denial%20of%20Petition_July%.2016%202014.pdf. Accessed April 28, 2016.

  11. Vigen R, O’Donnell CI, Barón AE, Grunwald GK, Maddox TM, Bradley SM, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA - J Am Med Assoc. 2013;310:1829–36. https://doi.org/10.1001/jama.2013.280386.

    Article  CAS  Google Scholar 

  12. Morgentaler A, Lunenfeld B. Testosterone and cardiovascular risk: World’s experts take unprecedented action to correct misinformation. Aging Male. 2014;17:63–65. https://doi.org/10.3109/13685538.2014.913413.

    Article  PubMed  Google Scholar 

  13. Finkle WD, Greenland S, Ridgeway GK, Adams JL, Frasco MA, Cook MB, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805 https://doi.org/10.1371/journal.pone.0085805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Woodcock J. Letter to Sidney Wolfe, M.D. and Michael Carome, M.D., responding to FDA-2014-P-0258, Public Citizen’s petition for boxed warning for testosterone-containing drugs. Food and Drug Administration. 2014. https://www.citizen.org/wp-content/uploads/migration/2184_fda_denial_of_petition_july_16_2014.pdf. Accessed June 2020.

  15. Xu L, Freeman G, Cowling BJ, Schooling CM. Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of placebo-controlled randomized trials. BMC Med. 2013;11:108 https://doi.org/10.1186/1741-7015-11-108.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. FDA Drug Safety Communication: FDA cautions about using testosterone products for low testosterone due to aging; requires labeling change to inform of possible increased risk of heart attack and stroke with use. 2015. http://www.fda.gov/Drugs/DrugSafety/ucm436259.htm.

  17. European Medicines Agency. No consistent evidence of an increased risk of heart problems with testosterone medicines. 87, 3632–9. www.ema.europa.eu/docs/en_GB/document_library/Press_release/2014/11/WC500177618.pdf. Accessed June, 2020.

  18. Mulhall JP, Trost LW, Brannigan RE, Kurtz EG, Redmon JB, Chiles KA, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200:423–32. https://doi.org/10.1016/j.juro.2018.03.115.

    Article  PubMed  Google Scholar 

  19. Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, et al. Testosterone therapy in men with hypogonadism: an endocrine society. J Clin Endocrinol Metab. 2018;103:1715–44. https://doi.org/10.1210/jc.2018-00229.

    Article  PubMed  Google Scholar 

  20. Soisson V, Brailly-Tabard S, Helmer C, Rouaud O, Ancelin ML, Zerhouni C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75:282–8. https://doi.org/10.1016/j.maturitas.2013.04.012.

    Article  CAS  PubMed  Google Scholar 

  21. Araujo AB, Dixon JM, Suarez EA, Murad MH, Guey LT, Wittert GA. Endogenous testosterone and mortality in men: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2011;96:3007–19. https://doi.org/10.1210/jc.2011-1137.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Malkin CJ, Pugh PJ, Morris PD, Asif S, Jones TH, Channer KS. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821–5. https://doi.org/10.1136/hrt.2010.195412.

    Article  CAS  PubMed  Google Scholar 

  23. Ohlsson C, Barrett-Connor E, Bhasin S, Orwoll E, Labrie F, Karlsson MK, et al. High serum testosterone is associated with reduced risk of cardiovascular events in elderly men: The MrOS (osteoporotic fractures in men) study in Sweden. J Am Coll Cardiol. 2011;58:1674–81. https://doi.org/10.1016/j.jacc.2011.07.019.

    Article  CAS  PubMed  Google Scholar 

  24. Hak AE, Witteman JCM, de Jong FH, Geerlings MI, Hofman A, Pols HAP. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the rotterdam study. J Clin Endocrinol Metab. 2002;87:3632–9. https://doi.org/10.1210/jcem.87.8.8762.

    Article  CAS  PubMed  Google Scholar 

  25. Corona G, Rastrelli G, Di Pasquale G, Sforza A, Mannucci E, Maggi M. Endogenous testosterone levels and cardiovascular risk: meta-analysis of observational studies. J Sex Med. 2018;15:1260–71. https://doi.org/10.1016/j.jsxm.2018.06.012.

    Article  PubMed  Google Scholar 

  26. Adelborg K, Rasmussen TB, Nørrelund H, Layton JB, Sørensen HT, Christiansen CF. Cardiovascular outcomes and all-cause mortality following measurement of endogenous testosterone levels. Am J Cardiol. 2019;123:1757–64. https://doi.org/10.1016/j.amjcard.2019.02.042.

    Article  CAS  PubMed  Google Scholar 

  27. Karakas M, Schäfer S, Appelbaum S, Ojeda F, Kuulasmaa K, Brückmann B, et al. Testosterone levels and type 2 diabetes—No correlation with age, differential predictive value in men and women. Biomolecules. 2018;8:76 https://doi.org/10.3390/biom8030076.

    Article  CAS  PubMed Central  Google Scholar 

  28. Zeller T, Schnabel RB, Appelbaum S, Ojeda F, Berisha F, Schulte-Steinberg B, et al. Low testosterone levels are predictive for incident atrial fibrillation and ischaemic stroke in men, but protective in women – results from the FINRISK study. Eur J Prev Cardiol. 2018;25:1133–9. https://doi.org/10.1177/2047487318778346.

    Article  PubMed  Google Scholar 

  29. Zeller T, Appelbaum S, Kuulasmaa K, Palosaari T, Blankenberg S, Jousilahti P, et al. Predictive value of low testosterone concentrations regarding coronary heart disease and mortality in men and women – evidence from the FINRISK97 study. J Intern Med. 2019;286:317–25. https://doi.org/10.1111/joim.12943.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Yeap BB, Alfonso H, Paul Chubb SA, Handelsman DJ, Hankey GJ, Almeida OP, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99:E9–E18. https://doi.org/10.1210/jc.2013-3272.

    Article  PubMed  Google Scholar 

  31. Brand JS, Rovers MM, Yeap BB, Schneider HJ, Tuomainen TP, Haring R, et al. Testosterone, sex hormone-binding globulin and the metabolic syndrome in men: an individual participant data meta-analysis of observational studies. PLoS One. 2014;9:e100409 https://doi.org/10.1371/journal.pone.0100409.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Lamm S, Chidakel A, Bansal R. Obesity and hypogonadism. Urol Clin North Am. 2016;43:239–45. https://doi.org/10.1016/j.ucl.2016.01.005.

    Article  PubMed  Google Scholar 

  33. O’Reilly MW, Glisic M, Kumarendran B, Subramanian A, Manolopoulos KN, Tahrani AA, et al. Serum testosterone, sex hormone-binding globulin and sex-specific risk of incident type 2 diabetes in a retrospective primary care cohort. Clin Endocrinol. 2019;90:145–54. https://doi.org/10.1111/cen.13862.

    Article  CAS  Google Scholar 

  34. Liu X, Jiang J, Liu X, Luo Z, Wang Y, Dong X, et al. Association of serum testosterone with different classes of glucose metabolism and the mediation effect of obesity: the Henan Rural Cohort Study. Diabetes Metab Res Rev. 2019;35:3133 https://doi.org/10.1002/dmrr.3133.

    Article  CAS  Google Scholar 

  35. Jones TH, Arver S, Behre HM, Buvat J, Meuleman E, Moncada I, et al. Testosterone replacement in hypogonadal men with Type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828–37. https://doi.org/10.2337/dc10-1233.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Sharma R, Oni OA, Gupta K, Chen G, Sharma M, Dawn B, et al. Normalization of testosterone level is associated with reduced incidence of myocardial infarction and mortality in men. Eur Heart J. 2015;36:2706–15. https://doi.org/10.1093/eurheartj/ehv346.

    Article  PubMed  Google Scholar 

  37. Sharma R, Oni OA, Gupta K, Sharma M, Sharma R, Singh V, et al. Normalization of testosterone levels after testosterone replacement therapy is associated with decreased incidence of atrial fibrillation. J Am Heart Assoc. 2017;6. https://doi.org/10.1161/JAHA.116.004880.

  38. Oni OA, Sharma R, Chen G, Sharma M, Gupta K, Dawn B, et al. Normalization of testosterone levels after testosterone replacement therapy is not associated with reduced myocardial infarction in smokers. Mayo Clin Proc Innov Qual Outcomes. 2017;1:57–66. https://doi.org/10.1016/j.mayocpiqo.2017.05.003.

    Article  PubMed  PubMed Central  Google Scholar 

  39. Etminan M, Skeldon SC, Goldenberg SL, Carleton B, Brophy JM. Testosterone therapy and risk of myocardial infarction: a pharmacoepidemiologic study. Pharmacotherapy. 2015;35:72–8. https://doi.org/10.1002/phar.1534.

    Article  CAS  PubMed  Google Scholar 

  40. Wallis CJD, Lo K, Lee Y, Krakowsky Y, Garbens A, Satkunasivam R, et al. Survival and cardiovascular events in men treated with testosterone replacement therapy: An intention-to-treat observational cohort study. Lancet Diabetes Endocrinol. 2016;4:498–506. https://doi.org/10.1016/S2213-8587(16)00112-1.

    Article  CAS  PubMed  Google Scholar 

  41. Traish AM, Haider A, Haider KS, Doros G, Saad F. Long-term testosterone therapy improves cardiometabolic function and reduces risk of cardiovascular disease in men with hypogonadism. J Cardiovasc Pharm Ther. 2017;22:414–33. https://doi.org/10.1177/1074248417691136.

    Article  CAS  Google Scholar 

  42. Cheetham TC, An JJ, Jacobsen SJ, Niu F, Sidney S, Quesenberry CP, et al. Association of testosterone replacement with cardiovascular outcomes among men with androgen deficiency. JAMA Intern Med. 2017;177:491–9. https://doi.org/10.1001/jamainternmed.2016.9546.

    Article  PubMed  Google Scholar 

  43. Saad F, Caliber M, Doros G, Haider KS, Haider A. Long-term treatment with testosterone undecanoate injections in men with hypogonadism alleviates erectile dysfunction and reduces risk of major adverse cardiovascular events, prostate cancer, and mortality. Aging Male. 2020;23:81–92. https://doi.org/10.1080/13685538.2019.1575354.

    Article  CAS  PubMed  Google Scholar 

  44. Zhang X, Huang K, Saad F, Haider KS, Haider A, Xu X. Testosterone Therapy Reduces Cardiovascular Risk Among Hypogonadal Men: A Prospective Cohort Study in Germany. Androg Clin Res Ther. 2021;2:64–72. https://doi.org/10.1089/andro.2020.0015.

  45. Kappert K, Böhm M, Schmieder R, Schumacher H, Teo K, Yusuf S, et al. Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease (TRANSCEND) and the ongoing telmisartan alone and in combinatio. Circulation. 2012;126:934–41. https://doi.org/10.1161/CIRCULATIONAHA.111.086660.

    Article  PubMed  Google Scholar 

  46. Kalin MF, Zumoff B. Sex hormones and coronary disease: a review of the clinical studies. Steroids. 1990;55:330–52. https://doi.org/10.1016/0039-128X(90)90058-J.

    Article  CAS  PubMed  Google Scholar 

  47. Alexandersen P, Haarbo J, Byrjalsen I, Lawaetz H, Christiansen C. Natural androgens inhibit male atherosclerosis: a study in castrated, cholesterol-fed rabbits. Circ Res. 1999;84:813–9. https://doi.org/10.1161/01.RES.84.7.813.

    Article  CAS  PubMed  Google Scholar 

  48. Nettleship JE, Jones TH, Channer KS, Jones RD. Physiological testosterone replacement therapy attenuates fatty streak formation and improves high-density lipoprotein cholesterol in the Tfm mouse: An effect that is independent of the classic androgen receptor. Circulation. 2007;116:2427–34. https://doi.org/10.1161/CIRCULATIONAHA.107.708768.

    Article  CAS  PubMed  Google Scholar 

  49. Bourghardt J, Wilhelmson ASK, Alexanderson C, De Gendt K, Verhoeven G, Krettek A, et al. Androgen receptor-dependent and independent atheroprotection by testosterone in male mice. Endocrinology. 2010;151:5428–37. https://doi.org/10.1210/en.2010-0663.

    Article  CAS  PubMed  Google Scholar 

  50. Iannantuoni F, Salazar JD, Martinez de Marañon A, Bañuls C, López-Domènech S, Rocha M, et al. Testosterone administration increases leukocyte-endothelium interactions and inflammation in transgender men. Fertil Steril. 2021;115:483–9. https://doi.org/10.1016/j.fertnstert.2020.08.002.

    Article  CAS  PubMed  Google Scholar 

  51. Malkin CJ, Pugh PJ, Jones RD, Kapoor D, Channer KS, Jones TH. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–8. https://doi.org/10.1210/jc.2003-031069.

    Article  CAS  PubMed  Google Scholar 

  52. Kelly DM, Jones TH. Testosterone and obesity. Obes Rev. 2015;16:581–606. https://doi.org/10.1111/obr.12282.

    Article  CAS  PubMed  Google Scholar 

  53. Haddad RM, Kennedy CC, Caples SM, Tracz MJ, Boloña ER, Sideras K, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc. 2007;82:29–39. https://doi.org/10.4065/82.1.29.

    Article  CAS  PubMed  Google Scholar 

  54. Langer C, Gansz B, Goepfert C, Engel T, Uehara Y, Von Dehn G, et al. Testosterone up-regulates scavenger receptor bi and stimulates cholesterol efflux from macrophages. Biochem Biophys Res Commun. 2002;296:1051–7. https://doi.org/10.1016/S0006-291X(02)02038-7.

    Article  CAS  PubMed  Google Scholar 

  55. Movérare-Skrtic S, Venken K, Andersson N, Lindberg MK, Svensson J, Swanson C, et al. Dihydrotestosterone treatment results in obesity and altered lipid metabolism in orchidectomized mice. Obesity. 2006;14:662–72. https://doi.org/10.1038/oby.2006.75.

    Article  PubMed  Google Scholar 

  56. Tenover JS. Effects of testosterone supplementation in the aging male. J Clin Endocrinol Metab. 1992;75:1092–8. https://doi.org/10.1210/jcem.75.4.1400877.

    Article  CAS  PubMed  Google Scholar 

  57. Ohlander SJ, Varghese B, Pastuszak AW. Erythrocytosis following testosterone therapy. Sex Med Rev. 2018;6:77–85. https://doi.org/10.1016/j.sxmr.2017.04.001.

    Article  PubMed  Google Scholar 

  58. Bachman E, Feng R, Travison T, Li M, Olbina G, Ostland V, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010;95:4743–7. https://doi.org/10.1210/jc.2010-0864.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Angelova P, Momchilova A, Petkova D, Staneva G, Pankov R, Kamenov Z. Testosterone replacement therapy improves erythrocyte membrane lipid composition in hypogonadal men. Aging Male. 2012;15:173–9. https://doi.org/10.3109/13685538.2012.693550.

    Article  CAS  PubMed  Google Scholar 

  60. Pastuszak AW, Gomez LP, Scovell JM, Khera M, Lamb DJ, Lipshultz LI. Comparison of the effects of testosterone gels, injections, and pellets on serum hormones, erythrocytosis, lipids, and prostate-specific antigen. Sex Med. 2015;3:165–73. https://doi.org/10.1002/sm2.76.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Eleawa SM, Sakr HF, Hussein AM, Assiri AS, Bayoumy NMK, Alkhateeb M. Effect of testosterone replacement therapy on cardiac performance and oxidative stress in orchidectomized rats. Acta Physiol. 2013;209:136–47. https://doi.org/10.1111/apha.12158.

    Article  CAS  Google Scholar 

  62. Golden KL, Marsh JD, Jiang Y, Moulden J. Acute actions of testosterone on contractile function of isolated rat ventricular myocytes. Eur J Endocrinol. 2005;152:479–83. https://doi.org/10.1530/eje.1.01845.

    Article  CAS  PubMed  Google Scholar 

  63. Bai CX, Kurokawa J, Tamagawa M, Nakaya H, Furukawa T. Nontranscriptional regulation of cardiac repolarization currents by testosterone. Circulation. 2005;112:1701–10. https://doi.org/10.1161/CIRCULATIONAHA.104.523217.

    Article  CAS  PubMed  Google Scholar 

  64. Zhang Y, Ouyang P, Post WS, Dalal D, Vaidya D, Blasco-Colmenares E, et al. Sex-steroid hormones and electrocardiographic qt-interval duration: findings from the third national health and nutrition examination survey and the multi-ethnic study of atherosclerosis. Am J Epidemiol. 2011;174:403–11. https://doi.org/10.1093/aje/kwr172.

    Article  PubMed  PubMed Central  Google Scholar 

  65. Vicente J, Johannesen L, Galeotti L, Strauss DG. Mechanisms of sex and age differences in ventricular repolarization in humans. Am Heart J. 2014;168:749–.e3. https://doi.org/10.1016/j.ahj.2014.07.010.

    Article  PubMed  Google Scholar 

  66. Salem JE, Waintraub X, Courtillot C, Shaffer CM, Gandjbakhch E, Maupain C, et al. Hypogonadism as a reversible cause of torsades de pointes in men. Circulation. 2018;138:110–3. https://doi.org/10.1161/CIRCULATIONAHA.118.034282.

    Article  PubMed  PubMed Central  Google Scholar 

  67. Malkin CJ, Pugh PJ, West JN, Van Beek EJR, Jones TH, Channer KS. Testosterone therapy in men with moderate severity heart failure: a double-blind randomized placebo controlled trial. Eur Heart J. 2006;27:57–64. https://doi.org/10.1093/eurheartj/ehi443.

    Article  CAS  PubMed  Google Scholar 

  68. Caminiti G, Volterrani M, Iellamo F, Marazzi G, Massaro R, Miceli M, et al. Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure. a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol. 2009;54:919–27. https://doi.org/10.1016/j.jacc.2009.04.078.

    Article  CAS  PubMed  Google Scholar 

  69. Jaffe MD. Effect of testosterone cypionate on postexercise ST segment depression. Heart. 1977;39:1217–22. https://doi.org/10.1136/hrt.39.11.1217.

    Article  CAS  Google Scholar 

  70. Rosano GMC, Leonardo F, Pagnotta P, Pelliccia F, Panina G, Cerquetani E, et al. Acute anti-ischemic effect of testosterone in men with coronary artery disease. Circulation. 1999;99:1666–70. https://doi.org/10.1161/01.CIR.99.13.1666.

    Article  CAS  PubMed  Google Scholar 

  71. Webb CM, Adamson DL, De Zeigler D, Collins P. Effect of acute testosterone on myocardial ischemia in men with coronary artery disease. Am J Cardiol. 1999;83:437–9. https://doi.org/10.1016/S0002-9149(98)00880-7.

    Article  CAS  PubMed  Google Scholar 

  72. Malkin CJ, Pugh PJ, Morris PD, Kerry KE, Jones RD, Jones TH, et al. Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life. Heart. 2004;90:871–6. https://doi.org/10.1136/hrt.2003.021121.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. Mathur A, Malkin C, Saeed B, Muthusamy R, Hugh Jones T, Channer K. Long-term benefits of testosterone replacement therapy on angina threshold and atheroma in men. Eur J Endocrinol. 2009;161:443–9. https://doi.org/10.1530/EJE-09-0092.

    Article  CAS  PubMed  Google Scholar 

  74. English KM, Steeds RP, Jones TH, Diver MJ, Channer KS. Low-dose transdermal testosterone therapy improves angina threshold in men with chromic stable angina: a randomized, double-blind, placebo-controlled study. Circulation. 2000;102:1906–11. https://doi.org/10.1161/01.CIR.102.16.1906.

    Article  CAS  PubMed  Google Scholar 

  75. Pugh PJ, Jones RD, West JN, Jones TH, Channer KS. Testosterone treatment for men with chronic heart failure. Heart. 2004;90:446–7. https://doi.org/10.1136/hrt.2003.014639.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Stout M, Tew GA, Doll H, Zwierska I, Woodroofe N, Channer KS, et al. Testosterone therapy during exercise rehabilitation in male patients with chronic heart failure who have low testosterone status: A double-blind randomized controlled feasibility study. Am Heart J. 2012;164:893–901. https://doi.org/10.1016/j.ahj.2012.09.016.

    Article  CAS  PubMed  Google Scholar 

  77. Paduch DA, Polzer PK, Ni X, Basaria S. Testosterone replacement in androgen-deficient men with ejaculatory dysfunction: a randomized controlled trial. J Clin Endocrinol Metab. 2015;100:2956–62. https://doi.org/10.1210/jc.2014-4434.

    Article  CAS  PubMed  Google Scholar 

  78. Basaria S, Travison TG, Alford D, Knapp PE, Teeter K, Cahalan C, et al. Effects of testosterone replacement in men with opioid-induced androgen deficiency: a randomized controlled trial. Pain. 2015;156:280–8. https://doi.org/10.1097/01.j.pain.0000460308.86819.aa.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Dhindsa S, Ghanim H, Batra M, Kuhadiya ND, Abuaysheh S, Sandhu S, et al. Insulin resistance and inflammation in hypogonadotropic hypogonadism and their reduction after testosterone replacement in men with type 2 diabetes. Diabetes Care. 2016;39:82–91. https://doi.org/10.2337/dc15-1518.

    Article  CAS  PubMed  Google Scholar 

  80. Konaka H, Sugimoto K, Orikasa H, Iwamoto T, Takamura T, Takeda Y, et al. Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: A multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl. 2016;18:25–34. https://doi.org/10.4103/1008-682X.148720.

    Article  CAS  PubMed  Google Scholar 

  81. Criqui MH, Denenberg JO, Ix JH, McClelland RL, Wassel CL, Rifkin DE, et al. Calcium density of coronary artery plaque and risk of incident cardiovascular events. JAMA - J Am Med Assoc. 2014;311:271–8. https://doi.org/10.1001/jama.2013.282535.

    Article  CAS  Google Scholar 

  82. Park HB, Heo R, Ó Hartaigh B, Cho I, Gransar H, Nakazato R, et al. Atherosclerotic plaque characteristics by CT angiography identify coronary lesions that cause ischemia: a direct comparison to fractional flow reserve. JACC Cardiovasc Imaging. 2015;8:1–10. https://doi.org/10.1016/j.jcmg.2014.11.002.

    Article  PubMed  PubMed Central  Google Scholar 

  83. Basaria S, Harman SM, Travison TG, Hodis H, Tsitouras P, Budoff M, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with lowor low-normal testosterone levels: a randomized clinical trial. JAMA - J Am Med Assoc. 2015;314:570 https://doi.org/10.1001/jama.2015.8881.

    Article  CAS  Google Scholar 

  84. Rastrelli G, Dicuio M, Reismann Y, Sforza A, Maggi M, Corona G. Cardiovascular impact of testosterone therapy for hypogonadism. Expert Rev Cardiovasc Ther. 2018;16:617–25. https://doi.org/10.1080/14779072.2018.1510314.

    Article  CAS  PubMed  Google Scholar 

  85. Corona G, Maseroli E, Rastrelli G, Isidori AM, Sforza A, Mannucci E, et al. Cardiovascular risk associated with testosterone-boosting medications: a systematic review and meta-Analysis. Expert Opin Drug Saf. 2014;13:1327–51. https://doi.org/10.1517/14740338.2014.950653.

    Article  CAS  PubMed  Google Scholar 

  86. Alexander GC, Iyer G, Lucas E, Lin D, Singh S. Cardiovascular risks of exogenous testosterone use among men: a systematic review and meta-analysis. Am J Med. 2017;130:293–305. https://doi.org/10.1016/j.amjmed.2016.09.017.

    Article  CAS  PubMed  Google Scholar 

  87. Kloner RA, Carson C, Dobs A, Kopecky S, Mohler ER. Testosterone and cardiovascular disease. J Am Coll Cardiol. 2016;67:545–57. https://doi.org/10.1016/j.jacc.2015.12.005.

    Article  CAS  PubMed  Google Scholar 

  88. Layton JB, Meier CR, Sharpless JL, Stürmer T, Jick SS, Brookhart MA. Comparative safety of testosterone dosage forms. JAMA Intern Med. 2015;175:1187–96. https://doi.org/10.1001/jamainternmed.2015.1573.

    Article  PubMed  PubMed Central  Google Scholar 

  89. Kharaba ZJ, Buabeid MA, Ibrahim NA, Jirjees FJ, Obaidi HJA, Kaddaha A, et al. Testosterone therapy in hypogonadal patients and the associated risks of cardiovascular events. Biomed Pharmacother. 2020;129:110423 https://doi.org/10.1016/j.biopha.2020.110423.

    Article  CAS  PubMed  Google Scholar 

  90. Kharaba ZJ, Buabeid MA, Alfoteih YA. Effectiveness of testosterone therapy in hypogonadal patients and its controversial adverse impact on the cardiovascular system. Crit Rev Toxicol. 2020;50:491–512. https://doi.org/10.1080/10408444.2020.1789944

    Article  CAS  PubMed  Google Scholar 

  91. Auerbach JM, Khera M. Hypogonadism management and cardiovascular health. Postgrad Med. 2020;132:35–41. https://doi.org/10.1080/00325481.2020.1805917.

    Article  PubMed  Google Scholar 

  92. Khera M, Miner M, Jaffe J, Pastuszak AW. Testosterone therapy and cardiovascular risk: a critical analysis of studies reporting increased risk. J Sex Med. 2021;18:83–98. https://doi.org/10.1016/j.jsxm.2020.10.019.

    Article  CAS  PubMed  Google Scholar 

  93. Ahmed T, Alattar M, Pantalone K, Haque R. Is testosterone replacement safe in men with cardiovascular disease? Cureus. 2020;12:7324 https://doi.org/10.7759/cureus.7324.

    Article  Google Scholar 

  94. Sesti F, Pofi R, Minnetti M, Tenuta M, Gianfrilli D, Isidori AM. Late-onset hypogonadism: reductio ad absurdum of the cardiovascular risk-benefit of testosterone replacement therapy. Andrology. 2020;8:1614–27. https://doi.org/10.1111/andr.12876.

    Article  CAS  PubMed  Google Scholar 

  95. Corona G, Torres LO, Maggi M. Testosterone therapy: what we have learned from trials. J Sex Med. 2020;17:447–60. https://doi.org/10.1016/j.jsxm.2019.11.270.

    Article  CAS  PubMed  Google Scholar 

  96. US National Library of Medicine. ClinicalTrials.gov. 2019. http://www.clinicaltrials.gov/ct2/show/NCT03518034.

Download references

Author information

Authors and Affiliations

Authors

Contributions

JA was responsible for conducting the search for eligible studies, screening eligible studies, interpreting results, original draft writing, and draft revision. MK was responsible for conceptualization, screening eligible studies, and draft revision.

Corresponding author

Correspondence to Jeremy M. Auerbach.

Ethics declarations

Competing interests

MK, MD, MBA, MPH. Consultant: Clarus, Boston Scientific, Metuchen, AbbVie. JA declares no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Auerbach, J.M., Khera, M. Testosterone replacement therapy and cardiovascular disease. Int J Impot Res 34, 685–690 (2022). https://doi.org/10.1038/s41443-021-00516-6

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41443-021-00516-6

This article is cited by

Search

Quick links